Clinical trials: Breast Cancer, Metastatic Breast Cancer
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci
Breast Cancer, Bone Metastases
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone.
- Trial name
- NCT00566618
- Testing
- Dasatinib, Zoledronic Acid
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Breast Cancer, Metastatic Breast Cancer
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.
- Trial name
- NCT04733417
- Testing
- SHR6390, famitinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer, Hormon Receptor Positive Breast Cancer
Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine…
- Trial name
- OCEAN (NCT07895160)
- Testing
- cResponse Ex Vivo Organ Culture (EVOC) Drug Sensitivity Assay
- Where
- Israel
- Volunteers
- 39 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Metastatic Breast Cancer
Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)
The progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy capecitabine.
- Trial name
- NCT01380808
- Testing
- capecitabine and pseudomonas aeruginosa combination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Breast Cancer
Spousal Relationships and Pain in Metastatic Breast Cancer
Ecological Momentary Assessment (EMA) refers to the collection of repeated measurements of phenomena as they occur in naturalistic settings using hand-held computers.
- Trial name
- NCT00386620
- Testing
- Questionnaire, Interview
- Where
- United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Hot Flashes
Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer
RATIONALE: The herbal supplement black cohosh may be effective in relieving hot flashes in women. PURPOSE: Randomized phase III trial to determine the effectiveness of black cohosh in relieving hot flashes in women who have…
- Trial name
- NCT00060320
- Testing
- black cohosh
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Metastases
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
RSR13 (efaproxiral) is a radiation sensitizer that has shown positive results in a Phase 3, randomized clinical trial of patients with brain metastases.
- Trial name
- ENRICH (NCT00083304)
- Testing
- Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
- Where
- 94 sites in United States, Argentina and 13 more
- Volunteers
- 368 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic).
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04871516
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost
- Where
- 11 sites in United States
- Volunteers
- 103 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Breast Cancer
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
Very few patients with endocrine-resistant, hormone-receptor positive metastatic breast cancer respond to single agent immunotherapy. Responses to chemotherapy are usually of short duration.
- Trial name
- KEYDOX (NCT03591276)
- Testing
- Chemotherapy Drugs, Cancer
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Shaare Zedek Medical Center
Breast Cancer
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
This is a multi-center, observational study designed to explore the regulatory mechanism of palbociclib correlative pathways in therapeutic process of breast cancer, employing next generation sequencing (NGS) on DNA and RNA.
- Trial name
- NCT04289974
- Testing
- Palbociclib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
- Trial name
- TB06 (NCT07205822)
- Testing
- Dato-DXd
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Breast Neoplasms, BRCA 1 Gene Mutation
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or…
- Conditions
- Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- EMBRACA (NCT01945775)
- Testing
- talazoparib, Physician's-Choice
- Where
- 362 sites in United States, Australia and 14 more
- Volunteers
- 431 people
- Sponsor
- Pfizer
Breast Cancer
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
Pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab.
- Trial name
- NCT00193076
- Testing
- Gemcitabine, Carboplatin, Trastuzumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus
- Trial name
- EVERIMMUN (NCT02854618)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Cancer
Abiraterone Acetate in Molecular Apocrine Breast Cancer
The purpose of this study is to estimate antitumour activity of abiraterone acetate in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
- Trial name
- AMA (NCT01842321)
- Testing
- Abiraterone Acetate
- Where
- 36 sites in France
- Volunteers
- 34 people
- Sponsor
- UNICANCER
Breast Neoplasm, Metastatic Breast Cancer
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).
- Conditions
- Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
- Trial name
- NCT02608216
- Testing
- [18F]FLT, PET/CT, ribociclib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Breast Cancer
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01022138
- Testing
- HER2Bi-armed activated T cells, Cyclophosphamide, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.